Uniting Minds to Push the Boundaries of Innovation

The forum centered on four core sessions: refining PCI practices through physiology and imaging, breaking technical bottlenecks in complex lesions, and exploring innovative applications of next-generation precision in atrial fibrillation. Experts engaged in dynamic discussions on challenging clinical cases, embodying the spirit of connecting wisdom, innovating beyond limits, and uniting for progress to navigate new frontiers in cardiovascular technology.

Dr. Song Liang, Chairman and CEO of Insight Lifetech, stated, "In the realm of healthcare innovation, collaboration is the driving force behind transformation. The 'CONNECT·INNOVATE·UNITE' vision of INSIGHT FORUM aligns perfectly with Insight Lifetech's mission—'Transforming healthcare through innovation and quality'. Starting from clinical needs, we continue to expand the boundaries of innovation. To date, our cardiovascular precision intervention solutions have benefited over 350,000 patients, covering 64 countries and serving more than 2,000 medical centers worldwide. We project to enhance the quality of life for over 250,000 more patients by 2025, which reflects the essence of medical innovation: transforming clinical insights into technological breakthroughs through cross-disciplinary collaboration, and addressing the profound needs of life health with goal-driven innovation."

Global Recognition for Insight Lifetech's Journey of Excellence

Prof. Emanuele Barbato, Former President of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), commented, "We, the practitioners dedicated to medical innovation, have long been steadfast allies walking side by side. Over the years, rooted in science, guided by practice, and measured by truth, we have witnessed Insight Lifetech's growth from exploration to maturity. I strongly endorse its grand vision—making clinical diagnosis and treatment more precise and accessible through innovation and quality. Over nine years, from initial acquaintance to deep understanding, every breakthrough of Insight Lifetech has relied on the in-depth participation of physicians. Looking ahead, I am looking forward to seeing Insight Lifetech forge a steadier and farther path in medical innovation, ensuring that technological progress truly benefits every patient."

Advancing Physiology and Intravascular Imaging

1. Physiology Assessment Excellence: Coronary physiology assessment, with FFR, IMR, and CFR as core components, has become pivotal for precise patient evaluation and optimized interventional decisions. Experts discussed strategies to integrate these tools into PCI practices, emphasizing their role in shifting clinical decisions from traditional "anatomical stenosis judgment" to "physiological ischemia assessment." Insight Lifetech's m-iMR technology, featuring dual-temperature sensors, was highlighted for overcoming the poor repeatability of traditional tools, accurately reflecting microcirculatory resistance, and supporting comprehensive coronary disease management.
2. Intravascular Imaging Practices: Since 2024–2025, intravascular imaging technology has been designated as a Class IA recommendation by ESC and ACC/AHA, establishing IVUS as a core technology for complex coronary intervention. Insight Lifetech's IVUS system received praise for its higher resolution (60MHz with 40μm imaging), faster pullback (10mm/s, reducing examination time by two-thirds), and the inSmartVision platform, which automates plaque analysis to optimize stent selection and placement—addressing key challenges in clinical application.

Precision in Complex Lesions Treatment

Experts delved into strategies for managing complex PCI cases, emphasizing the integration of IVUS and FFR for precise decision-making. Clinical data presented showed that intravascular imaging-guided complex PCI reduces all-cause mortality by 25%, stent thrombosis by 50%, and unnecessary stent implantation by 23%. Case studies highlighted how Insight Lifetech's tools, such as the TrueCross™ microcatheter and TRUEVISION™ IVUS catheter, enhance procedural success in challenging scenarios like calcified lesions and CTOs.

Landmark PFA Research to Debut at ESC Congress 2025

A groundbreaking randomized controlled trial (RCT) on LotosPFA™, led by Prof. Xue Yumei (Guangdong Provincial People's Hospital) with 13 Chinese centers, will be featured in the Late-Breaking Clinical Trials session at ESC Congress 2025 (Madrid, September 1). The study compares nanosecond PFA vs. RFA, marking a milestone for Chinese innovation in global electrophysiology.

A Commitment to Future Innovation

INSIGHT FORUM 2025 fostered global collaboration, igniting new ideas and common objectives in cardiovascular care. Insight Lifetech is committed to sustaining its efforts in driving  technological breakthroughs and refining solutions.